Nav: Home

In a bad flu season, high-dose flu vaccine appeared better at preventing deaths in seniors

March 02, 2017

The high-dose flu vaccine appeared to be more effective at preventing post-influenza deaths among older adults than the standard-dose vaccine, at least during a more severe flu season, according to a large new study of Medicare beneficiaries published in The Journal of Infectious Diseases. The findings build on earlier research suggesting that the high-dose vaccine may be better at preventing influenza virus infections and other flu-related outcomes in seniors, including office visits and hospitalizations, compared to the standard-dose vaccine.

Older adults are at high risk for serious complications from flu because of their age. In recent years, between 71 percent and 85 percent of flu-related deaths have occurred among people 65 years of age and older, according to estimates from the Centers for Disease Control and Prevention (CDC). The high-dose flu vaccine was approved in 2009 in the U.S. for adults 65 and older. "This is the population that everybody worries about," said study author David K. Shay, MD, MPH, of CDC's Influenza Division. "Many of the most serious outcomes of flu infections occur in older people."

In the study, researchers from CDC, the Centers for Medicare & Medicaid Services, and the Food and Drug Administration drew on data from Medicare beneficiaries aged 65 or older who received either the high-dose or standard-dose flu vaccine during the 2012-2013 and 2013-2014 flu seasons from community-located pharmacies. More than a million recipients of each vaccine type were studied in each of the two seasons.

During the 2012-2013 season, people who got a high-dose vaccine were 36 percent less likely to die in the 30 days following hospitalization or an emergency department visit that included a flu diagnosis compared to the standard-dose vaccine, the researchers found. H3N2 influenza viruses, which are usually associated with higher mortality in older adults, were predominant during that season. During the following season (2013-2014), when H1N1 viruses dominated and the standard-dose vaccine had better effectiveness than the previous season, the high-dose vaccine was not significantly better at preventing deaths among the Medicare patients studied.

"The high dose vaccine does appear, at least in this particular H3N2 season, to be more effective at preventing deaths that occur within 30 days of an influenza hospitalization," Dr. Shay said. "We didn't see a significant effect on post-influenza deaths during the 2013-2014 H1N1 season."

In a related editorial commentary, Arnold S. Monto, MD, of the University of Michigan School of Public Health, who was not involved in the study, noted that the findings fit well with previous data showing the high-dose flu vaccine is more effective against uncomplicated flu illness and likely hospitalizations. "This indicates that improvement in our 70-year-old influenza vaccines is possible, and to get there more quickly we should not ignore older technologies while working on more dramatic advances," Dr. Monto wrote.

Fast Facts
  • Older adults are at high risk for serious complications from flu and account for a majority of flu-related deaths and hospitalizations. H3N2 influenza viruses typically hit this age group particularly hard and have been associated with higher mortality than infections by H1N1 or influenza B viruses.
  • During the 2012-2013 season, when H3N2 viruses were dominant, the high-dose flu vaccine was 36 percent more effective at preventing deaths in the Medicare beneficiaries studied, compared to the standard-dose vaccine.
  • When H1N1 viruses circulated during the 2013-2014 season, the high-dose vaccine was not significantly better than the standard-dose vaccine at preventing deaths.
-end-
Editor's Note: The study was funded by Centers for Disease Control and Prevention and the Food and Drug Administration. The study authors' and editorial commentary authors' affiliations, acknowledgments, and disclosures of financial support and potential conflicts of interests, if any, are available in the study and the commentary, which are embargoed until 12:05 a.m. ET on Thursday, March 2. For an embargoed copy of the study and the commentary, please contact Jeremy Andereck (312-558-1770, jandereck@pcipr.com).

Published continuously since 1904, The Journal of Infectious Diseases is the premier global journal for original research on infectious diseases. The editors welcome major articles and brief reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. The journal is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing nearly 10,000 physicians and scientists who specialize in infectious diseases. For more information, visit http://www.idsociety.org. Follow IDSA on Facebook and Twitter.

Infectious Diseases Society of America

Related Influenza Articles:

Birds become immune to influenza
An influenza infection in birds gives a good protection against other subtypes of the virus, like a natural vaccination, according to a new study.
Researchers shed new light on influenza detection
Notre Dame Researchers have discovered a way to make influenza visible to the naked eye, by engineering dye molecules to target a specific enzyme of the virus.
Maternal vaccination again influenza associated with protection for infants
How long does the protection from a mother's immunization against influenza during pregnancy last for infants after they are born?
Influenza in the tropics shows variable seasonality
Whilst countries in the tropics and subtropics exhibit diverse patterns of seasonal flu activity, they can be grouped into eight geographical zones to optimise vaccine formulation and delivery timing, according to a study published April 27, 2016 in the open-access journal PLOS ONE.
Influenza viruses can hide from the immune system
Influenza is able to mask itself, so that the virus is not initially detected by our immune system.
Using 'big data' to combat influenza
Team of scientists from the Icahn School of Medicine at Mount Sinai and Sanford Burnham Prebys Medical Discovery Institute among those who combined large genomic and proteomic datasets to identify novel host targets to treat flu.
Rapidly assessing the next influenza pandemic
Influenza pandemics are potentially the most serious natural catastrophes that affect the human population.
Early detection of highly pathogenic influenza viruses
Lack of appropriate drugs and vaccines during the influenza A virus pandemic in 2009, the recent Ebola epidemic in West Africa, as well as the ongoing Middle Eastern Respiratory Syndrome-Coronavirus outbreak demonstrates that the world is only insufficiently prepared for global attacks of emerging infectious diseases and that the handling of such threats remains a great challenge.
Study maps travel of H7 influenza genes
In a new bioinformatics analysis of the H7N9 influenza virus that has recently infected humans in China, researchers trace the separate phylogenetic histories of the virus's genes, giving a frightening new picture of viruses where the genes are traveling independently in the environment, across large geographic distances and between species, to form 'a new constellation of genes -- a new disease, based not only on H7, but other strains of influenza.'
Influenza A potentiates pneumococcal co-infection: New details emerge
Influenza infection can enhance the ability of the bacterium Streptococcus pneumoniae to cause ear and throat infections, according to research published ahead of print in the journal Infection and Immunity.

Related Influenza Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...